• An analyst from Veritas Investment Research set a new price target of $31.00 for STAAR Surgical, indicating a potential 48.54% upside for the eyecare specialist.
  • STAAR Surgical's board authorized a significant $50 million share repurchase program, signaling confidence in the company's future and potentially boosting shareholder value.
  • Despite a "value trap" warning, valuation metrics like a GF Value of $33.28 and substantial insider buying of $62.7 million suggest potential undervaluation for STAAR Surgical.

STAAR Surgical Company (NASDAQ:STAA) is an eyecare specialist that designs, develops, and sells implantable lenses for the eye. An analyst from Veritas Investment Research recently set a new price target for STAAR Surgical at $31.00. This suggests a potential 48.54% increase from the stock's price of $20.87 at the time of the announcement.

This optimistic outlook follows a key strategic move by the company. STAAR Surgical's board of directors has authorized a share repurchase program for up to $50 million of its stock, as detailed in the Business Wire announcement. A share buyback is when a company buys its own shares from the market, which can increase the value of the remaining shares.

The market reacted positively to the buyback news, with STAAR Surgical's stock finishing a recent Friday session more than 7% higher. The eyecare stock currently trades at $20.87, with a daily trading range between $20.28 and $20.96. Over the past year, the stock has fluctuated between a low of $15.59 and a high of $35.87.

Valuation metrics also suggest the stock may be undervalued. As highlighted by GuruFocus, STAAR Surgical's estimated fair value, or GF Value, is $33.28, which is significantly higher than a recent closing price of $19.80. However, GuruFocus also notes that the stock could be a possible value trap, which means it may appear cheap but has underlying problems.

Further supporting a positive view, insiders have purchased $62.7 million worth of shares in the last year with no reported selling. The company also holds a GF Score of 76 out of 100, which suggests it has the potential for above-average performance. The company's current market capitalization is approximately $1.04 billion.